Mesenchymal Stem Cell Applications for the Treatment of COVID-19: Clinical Perspective

named "2019 Novel Coronavirus" (2019-nCoV) by the World Health Organization (WHO).While the disease was named as Coronavirus disease 2019 (COVID-19) by WHO, the Coronavirus Working Group (CSG) of the International Committee on Virus Taxonomy has identified 2019-nCoV as the sister of severe acute respiratory syndrome coronaviruses (SARS-CoV), which appeared in 2002 andcaused fatal respiratory illness in humans [1], based on its phylogenetic and taxonomic relationships and have published a study in which they propose to name severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2,3].On February 19, 2020, a group of virologists suggested that it is different from SARS-CoV in terms of its biological, epidemiological and clinical features and that it is incorrect to call 2019-nCoV as SARS-CoV-2.Based on the clinical, virological and epidemiological features and the uncertainty of the novel coronavirus, they named the disease human coronavirus 2019 (hCoV-19) [4].SARS-CoV-2 term is commonly used in many studies in despite of the disaggreements between the different virologist groups on the nomenclature of the virus.SARS-CoV-2, identified as a novel RNA coronavirus and belongs to the same family with SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), has RNA nucleic acid which is approximately 30 kb Review ARTicle